Bernstein Maintains Outperform on Guardant Health, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
Bernstein analyst Eve Burstein maintains an Outperform rating on Guardant Health but lowers the price target from $40 to $35.
October 30, 2024 | 6:56 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bernstein analyst Eve Burstein maintains an Outperform rating on Guardant Health but lowers the price target from $40 to $35.
The Outperform rating suggests a positive outlook, but the lowered price target indicates some concerns or adjustments in expectations. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100